-
Mashup Score: 4
The Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Patient Registry registry powered by NORD platform.
Source: pnh.iamrare.orgCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 4
The Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Patient Registry registry powered by NORD platform.
Source: pnh.iamrare.orgCategories: General Medicine News, Rare DiseaseTweet-
Hear what other participants are saying about the Global #PNH Patient Registry! Do you want to be a part of this important research too? Learn more at https://t.co/EgBjcFvgTA https://t.co/yjHwX6O4un
-
-
Mashup Score: 4
The Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Patient Registry registry powered by NORD platform.
Source: pnh.iamrare.orgCategories: General Medicine News, Rare DiseaseTweet-
Hear what other participants are saying about the Global #PNH Patient Registry! Do you want to be a part of this important research too? Learn more at https://t.co/EgBjcFvgTA https://t.co/yjHwX6O4un
-
-
Mashup Score: 2Voydeya (danicopan) granted first-ever regulatory approval in Japan for adults with PNH to be used in combination with C5 inhibitor therapy - 3 month(s) ago
Voydeya (danicopan) has been approved in Japan for the treatment of paroxysmal nocturnal hae moglobinuria (PNH). It is indicated in Japan in combination with C5 inhibitor therapy when patients have had an insufficient response to such C5 inhibitors. 1 Voydeya is a first-in-class, oral, Factor D inhibitor developed as add-on to proven standard-of-care Ultomiris or Soliris to address the needs of the subset of patients (approximately 10-20%) with PNH who experience clinically significant extravascular
Source: www.astrazeneca.comCategories: General Medicine News, PayerTweet-
For Media/Investors: Today, we’re excited to announce that our add-on treatment for certain adults with #PNH has been granted its first-ever regulatory approval in Japan. Learn more: https://t.co/gTZONlompU https://t.co/igOL4E7r68
-
-
Mashup Score: 4
The Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Patient Registry registry powered by NORD platform.
Source: pnh.iamrare.orgCategories: General Medicine News, Rare DiseaseTweet-
Hear what other participants are saying about the Global #PNH Patient Registry! Do you want to be a part of this important research too? Learn more at https://t.co/EgBjcFvgTA https://t.co/yjHwX6O4un
-
-
Mashup Score: 0Extension Period Findings Support Potential of Doublet Regimen In PNH | Docwire News - 5 month(s) ago
Pozelimab plus cemdisiran achieved intravascular hemolysis control in patients with paroxysmal nocturnal hemoglobinuria.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
From the @ASH_hematology Annual Meeting: pozelimab plus cemdisiran achieved long-term control of intravascular hemolysis among participants diagnosed with paroxysmal nocturnal hemoglobinuria in a phase II trial extension. Read more on: https://t.co/IHActamP8n hematology #pnh https://t.co/CVzE237It1
-
-
Mashup Score: 4
The Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Patient Registry registry powered by NORD platform.
Source: pnh.iamrare.orgCategories: General Medicine News, Rare DiseaseTweet-
Hear what other participants are saying about the Global #PNH Patient Registry! Do you want to be a part of this important research too? Learn more at https://t.co/EgBjcFvgTA https://t.co/yjHwX6O4un
-
-
Mashup Score: 0Multidisciplinary Conversations on Paroxysmal Nocturnal Hemoglobinuria: How to Involve Patients in the Management of Their Disease - 7 month(s) ago
Did you know that intravascular and extravascular hemolyses are the 2 hemolytic pathways underlying paroxysmal nocturnal hemoglobinuria (PNH)?
Source: www.medscape.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
📍 Did you know that intravascular and extravascular hemolyses are the 2 hemolytic pathways underlying paroxysmal nocturnal hemoglobinuria? #PNH #RareDisease #CardioX #CME ➡️ https://t.co/jpUdvErieY https://t.co/CNeqcm4dBT
-
-
Mashup Score: 0Eculizumab Is Effective for Thromboembolic Events in Patients With Paroxysmal Nocturnal Hemoglobinuria - 7 month(s) ago
Home > PNH > Eculizumab Is Effective for Thromboembolic Events in Patients With Paroxysmal Nocturnal Hemoglobinuria The international PNH Registry conducted a prospective, multicenter, observational study that evaluated the overall survival (OS) and first occurrence of thromboembolic events/major adverse vascular events (TEs/MAVEs) in patients with paroxysmal nocturnal hemoglobinuria (PNH) treat ed with eculizumab. Conducted over a period of 15 years, the study included 4118 patients with PNH. Patients
Source: docwirenews.comCategories: Latest Headlines, Partners & KOLsTweet-
A study assessed survival and adverse events in patients with paroxysmal nocturnal hemoglobinuria treated with #eculizumab. https://t.co/XltlcyUeXa #PNH #hematology https://t.co/QamLS4OuJs
-
-
Mashup Score: 0Multidisciplinary Conversations on Paroxysmal Nocturnal Hemoglobinuria: How to Involve Patients in the Management of Their Disease - 7 month(s) ago
Did you know that intravascular and extravascular hemolyses are the 2 hemolytic pathways underlying paroxysmal nocturnal hemoglobinuria (PNH)?
Source: www.medscape.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
📍 Did you know that intravascular and extravascular hemolyses are the 2 hemolytic pathways underlying paroxysmal nocturnal hemoglobinuria? #PNH #RareDisease #CardioX #CME ➡️ https://t.co/mn59CWO8vc https://t.co/3cD0nsVSc1
-
Hear what other participants are saying about the Global #PNH Patient Registry! Do you want to be a part of this important research too? Learn more at https://t.co/EgBjcFvgTA https://t.co/yjHwX6O4un